A Two-Sequence, Four-Period, Crossover, Full-Replicate Study to Demonstrate Bioequivalence of Carbamazepine Extended-Release Tablets in Healthy Subjects under Fasting and Fed Conditions
Abstract
Carbamazepine is a first-line antiepileptic drug (AED) used for the treatment of partial and tonic-clonic seizures. We conducted an open label, balanced, randomized, two-treatment, two-sequence, four-period, single oral dose, full-replicate crossover study to assess and compare the bioequivalence of test product Carbamazepine extended release tablets USP 400 mg with reference product Tegretol®-XR 400 mg (Carbamazepine extended release tablets), respectively in healthy subjects under fasting and fed conditions. Blood samples were collected pre-dose and at regular intervals post-dose up to 240.00 hours. The plasma concentration was analyzed by a validated LC-MS/MS method and the reference-scaled and the unscaled procedure was used to determine bioequivalence for the pharmacokinetics parameters, Cmax, AUC0–t, AUC0-inf, Tmax, T½, Kel and AUC extrapolated was calculated. The results showed that the geometric mean ratios of Cmax, AUC0–t and AUC0-inf were 113.04%, 108.33% and 108.15% respectively, in the fasting conditions and 113.99%, 110.13% and 111.41%, respectively, in the fed conditions and the 90% confidence intervals were all within the range of 80.00% to 125.00%. It can be concluded from the result that the test product Carbamazepine extended release tablets based on osmotic release system (OROS) are bioequivalent to the reference product Tegretol®-XR tablets.
Keywords: Bioequivalence, Carbamazepine, Sodium Channel Modulators and Epilepsy
Keywords:
Bioequivalence, Carbamazepine, Sodium Channel Modulators and EpilepsyDOI
https://doi.org/10.22270/jddt.v12i3-S.5404References
Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015 Sep; 17(3):243-53. PMID: 26234761. https://doi.org/10.1684/epd.2015.0751
World health organization, Epilepsy, Available at: https://www.who.int/news-room/fact-sheets/detail/epilepsy, Date [ 9 Feb 2022]
Goldenberg, Marvin M. "Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment." Pharmacy and Therapeutics 2010; 35(7):392
Tolou-Ghamari, Z., Zare, M., Habibabadi, J. M., & Najafi, M. R. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2013; 18(Suppl 1):S81-S85
Dean L. Carbamazepine Therapy and HLA Genotype. 2015 Oct 14 [updated 2018 Aug 1]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. PMID: 28520367
Lo, J. Carbamazepine. Encyclopedia of Toxicology, 2014; 665-667. https://doi.org/10.1016/B978-0-12-386454-3.00705-3
Koester, Letícia & Costa, Teresa & Bassani, Valquiria. Pharmacokinetics of carbamazepine from extended release dosage forms: Bioavailability/bioequivalence and in vitro-in vivo correlation studies. Journal of Drug Delivery Science and Technology. 2004; 14:401-407. https://doi.org/10.1016/S1773-2247(04)50070-9
Thakker KM, Mangat S, Garnett WR, Levy RH, Kochak GM. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. Biopharm Drug Dispos. 1992 Nov; 13(8):559-69. PMID: 1421050 https://doi.org/10.1002/bdd.2510130802
FDA Draft Guidance of carbamazepine available at: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_ER%20tab_020234_RV03-15.pdf
Eckenhoff B, Theeuwes F, Urquhart J. Osmotically actuated dosage forms for rate-controlled drug delivery. Pharmaceutical Technology. 1981; 5(1):35-44
Gatlewar S, Meshram R, Gangane P, Mahapatra, D, Mahajan N. Rational Development of Carbamazepine Osmotic Controlled Release Oral Delivery System for Multiple Therapeutic Advantages. International Journal of Current Research and Review. 2020; 12:43-48. https://doi.org/10.31782/IJCRR.2020.122406
Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. Journal of Controlled Release. 1995; 35(1):1-21 https://doi.org/10.1016/0168-3659(95)00013-X
Verma RK, Garg S. Development and evaluation of osmotically controlled oral drug delivery system of glipizide. European Journal of Pharmaceutics and Biopharmaceutics. 2004; 57(3):513-525 https://doi.org/10.1016/j.ejpb.2004.02.003
Published
Abstract Display: 1462 
PDF Downloads: 966 PDF Downloads: 218 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.